ImmunityBio’s IBRX QUILT-2.005 trial tops enrollment forecasts; BLA filing targeted by year-end after positive ANKTIVA+BCG ...
Despite 700% net product revenue growth to $113 million, ImmunityBio's high debt load and unprofitability remain significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback